ArticleCancer research2009
Reduced tumor necrosis factor receptor-associated death domain expression is associated with prostate cancer progression.
Article in Cancer research, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed.
- RELA is sufficient to mediate interleukin-1 repression of androgen receptor expression and activity in an LNCaP disease progression model.The Prostate · 2020Article
- Article
- Cholesterol Sulfotransferase SULT2B1b Modulates Sensitivity to Death Receptor Ligand TNFα in Castration-Resistant Prostate Cancer.Molecular cancer research : MCR · 2019Article
- Inflammation and NF-κB Signaling in Prostate Cancer: Mechanisms and Clinical Implications.Cells · 2018Review
- Secretory leukocyte protease inhibitor is a survival and proliferation factor for castration-resistant prostate cancer.Oncogene · 2016Article
- Curcumin sensitizes human gastric cancer cells to 5-fluorouracil through inhibition of the NFκB survival-signaling pathway.OncoTargets and therapy · 2016Article
- Combination simvastatin and metformin induces G1-phase cell cycle arrest and Ripk1- and Ripk3-dependent necrosis in C4-2B osseous metastatic castration-resistant prostate cancer cells.Cell death & disease · 2014Article
- Cytokine effects on cell viability and death of prostate carcinoma cells.BioMed research international · 2014Article
- False-positive TUNEL staining observed in SV40 based transgenic murine prostate cancer models.Transgenic research · 2013Article
- Roles of the Skp2/p27 axis in the progression of chronic nephropathy.Cellular and molecular life sciences : CMLS · 2013Review
- Androgens regulate TRAIL-induced cell death in prostate cancer cells via multiple mechanisms.Cancer letters · 2013Article
- TNFR-1 on tumor cells contributes to the sensitivity of fibrosarcoma to chemotherapy.Protein & cell · 2013Article
- Diabetes protects from prostate cancer by downregulating androgen receptor: new insights from LNCaP cells and PAC120 mouse model.PloS one · 2013Article
- NF-κB signaling in prostate cancer: a promising therapeutic target?World journal of urology · 2012Review
- TRADD contributes to tumour suppression by regulating ULF-dependent p19Arf ubiquitylation.Nature cell biology · 2012Article
- Paradoxical roles of tumour necrosis factor-alpha in prostate cancer biology.Prostate cancer · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
By using LNCaP and its derivative cell lines, we first observed an association between tumor necrosis factor-alpha (TNF-alpha) resistance and hormone independence. Moreover, we found that the expression of tumor necrosis factor receptor-associated death domain (TRADD) was reduced in androgen deprivation-independent cells compared with that in androgen deprivation-dependent cells. TRADD is a crucial transducer for TNF-alpha-induced nuclear factor-kappaB (NF-kappaB) activation. Knocking down TRADD expression in LNCaP cells impaired TNF-alpha-induced NF-kappaB activation and androgen receptor repression, whereas overexpression of TRADD in C4-2B cells restored their sensitivity to TNF-alpha. Finally, we found that androgen deprivation reduces TRADD expression in vitro and in vivo, suggesting that androgen deprivation therapy may promote the development of TNF-alpha resistance by reducing TRADD expression during prostate cancer progression.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.